J Korean Med Sci.  2010 Jul;25(7):1041-1044. 10.3346/jkms.2010.25.7.1041.

Predictors of Resolution of Hypertension after Adrenalectomy in Patients with Aldosterone-producing Adenoma

• Kim RM
• Lee J
• Soh EY

• KMID: 1792954
• DOI: http://doi.org/10.3346/jkms.2010.25.7.1041

Abstract

Primary aldosteronism (PA) is a frequent cause of secondary hypertension and is amenable to surgical intervention when it is caused by aldosterone-producing adenoma (APA). Many patients, however, continue to require antihypertensive medications to control their blood pressure after adrenalectomy. The aim of this study was to determine the preoperative factors that predict clinical outcomes after adrenalectomy in patients with APA. We studied 27 patients (mean age 45+/-4 yr) who had APA and underwent unilateral adrenalectomy between December 1995 and September 2008 at our institution. Clinical and biochemical data were evaluated at baseline and after a mean follow-up of 51.8+/-47.0 months (range, 6-159). At the end of the follow-up, 16 patients (59.3%) were considered to experience "complete resolution" without postoperative medications, whereas 7 patients (25.9%) "improved" with medications and 4 patients (14.8%) were "uncontrolled." Three factors (< or =2 antihypertensive medications [P=0.007], duration of hypertension <6 yr [P=0.002], and serum aldosterone <350 pg/mL [P<0.001]) were the predictive for complete resolution in univariate analysis. Multivariate regression analysis showed that serum aldosterone level (<350 pg/mL) was the single most important factor that predicted complete resolution after surgery (P<0.001). The best preoperative clinical factor that predicted resolution of postoperative hypertension after adrenalectomy is serum aldosterone level (<350 pg/mL).

Keyword

Primary Aldosteronism; Resistant Hypertension; Adrenal Glands

MeSH Terms

*Adrenalectomy
*Adrenocortical Adenoma/complications/surgery
Adult
Aldosterone/*blood
Female
Humans
*Hyperaldosteronism/complications/surgery
*Hypertension/etiology/surgery
Male
Middle Aged
Retrospective Studies
Treatment Outcome

Figure

• 

  Fig. 1 Rationale for the selection of 350 pg/mL as the cutoff for the plasma serum aldosterone level.

Reference

1. Streeten DH, Anderson GH. Secondary hypertension. An overview of its causes and management. Drugs. 1992. 43:805–819.

2. Young WF Jr. Primary aldosteronism: a common and curable form of hypertension. Cardiol Rev. 1999. 7:207–214.

3. Lund JO, Nielsen MD, Giese J. Prevalence of primary aldosteronism. Acta Med Scand Suppl. 1981. 646:54–57.

4. Anderson GH Jr, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens. 1994. 12:609–615.

5. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006. 48:2293–2300.

6. Zarnegar R, Young WF Jr, Lee J, Sweet MP, Kebebew E, Farley DR, Thompson GB, Grant CS, Clark OH, Duh QY. The Aldosteronoma resolution score predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. Ann Surg. 2008. 247:511–518.

7. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008. 168:80–85.

8. Pang TC, Bambach C, Monaghan JC, Sidhu SB, Bune A, Delbridge LW, Sywak MS. Outcomes of laparoscopic adrenalectomy for hyperladosteronism. ANZ Surg. 2007. 77:768–773.

9. Sawka AM, Young WF, Thompson GB, Grant CS, Farley DR, Leibson C, van Heerden JA. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med. 2001. 135:258–261.

10. Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan ED Jr, Sos TA, Atlas SA, Müller FB, Acevedo R, Ulick S, Laragh JH. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med. 1994. 121:877–885.

11. Rayner B. Primary aldosteronism and aldosterone-associated hypertension. J Clin Pathol. 2008. 61:825–831.

12. Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, Papadopoulos N, Vogiatzis K, Zamboulis C. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet. 2008. 371:1921–1926.

13. Rossi GP, Pessina AC. Blood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism with or without unilateral adenoma. J Hypertens. 2009. 27:656–659.

14. Carey RM. Primary aldosteronism. Horm Res. 2009. 71:Suppl 1. 8–12.

15. Gaddam KK, Pimenta E, Husain S, Calhoun DA. Aldosterone and cardiovascular disease. Curr Probl Cardiol. 2009. 34:51–84.

16. Conn JW, Louis LH. Primary aldosteronism, a new clinical entity. Ann Intern Med. 1956. 44:1–15.

17. Calhoun DA. Aldosteronism and hypertension. Clin J Am Soc Nephrol. 2006. 1:1039–1045.

18. Loh KC, Koay ES, Emmanuel SC, Young WF Jr. Prevalence of primary aldosteronism among Asian hypertensive patient in Singapore. J Clin Endocrinol Metab. 2000. 85:2854–2859.

19. Plouin PF, Amar L, Chatellier G. Trends in the prevalence of primary aldosteronism, alsoterone-producing adenomas, and surgically correctable aldosterone-dependent hypertension. Nephrol Dial Transplant. 2004. 19:774–777.

20. Rossi GP. Primary aldosteronism: a needle in a haystack or a yellow cab on Fifth Avenue? Curr Hypertens Rep. 2004. 6:1–4.

21. Young WF Jr. Primary aldosteronism: update on diagnosis and treatment. Endocrinologist. 1997. 7:213–221.

22. Ganguly A. Primary aldosteronism. N Engl J Med. 1998. 17(339):1828–1834.

23. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E. Selective aldosterone blockade prevents angiotensin II/salt induced vascular inflammation in the rat heart. Endocrinology. 2002. 143:4828–4836.

24. Chang MC, Noh DY, Youn YK, Choe KJ, Oh SK. Factors influencing outcome of surgical treatment for primary aldosteronism. J Korean Surg Soc. 2002. 62:308–313.

25. Reincke M, Rump LC, Quinkler M, Hahner S, Diederich S, Lorenz R, Seufert J, Schirpenbach C, Beuschlein F, Bidlingmaier M, Meisinger C, Holle R, Endres S. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab. 2009. 94:869–875.

26. Mourad JJ, Girerd X, Milliez P, Lopez-Sublet M, Lejeune S, Safar ME. Urinary aldosterone-to-active-renin ratio: a useful tool for predicting resolution of hypertension after adrenalectomy in patients with aldosterone-producing adenomas. Am J Hypertens. 2008. 21:742–747.